Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)

Yuankai Shi, Lin Wang, Runxiang Yang et al.|Journal of Thoracic Oncology|2024

Cited by 40